Robotic surgery may improve metabolic outcomes in type 2 diabetes
This study evaluated robotic surgical strategies for managing Type 2 diabetes, showing promising outcomes in weight loss and insulin reduction.
Research feed
Recently added diabetes research, organized by intervention and outcome.
Sorted by when Dediabetes added each study.
This study evaluated robotic surgical strategies for managing Type 2 diabetes, showing promising outcomes in weight loss and insulin reduction.
This study evaluated the efficacy of Sarcomeal supplement and vitamin D3 on muscle parameters in diabetic sarcopenia patients, revealing significant improvements in lean body mass and lean mass index.
This study evaluated the effectiveness of scalable diabetes self-management education and support models in adults with Type 2 Diabetes. Results showed no significant changes in key health outcomes.
This study evaluated the impact of a self-compassion intervention on diabetes distress and glycemic control in adolescents and young adults with Type 1 diabetes, finding significant improvement in HbA1c levels.
This study evaluated the cardiorenal effects of semaglutide in individuals with type 2 diabetes at high cardiovascular risk, finding significant reductions in major adverse cardiovascular events.
The study evaluated semaglutide, a glucagon-like peptide-1 receptor agonist, for managing high cardiovascular risk and found significant reductions in major renal events and cardiovascular risks.
This study compared once-weekly semaglutide to thrice-daily insulin aspart in adults with type 2 diabetes, revealing significant differences in HbA1c and body weight outcomes.
This study evaluated the impact of semaglutide on kidney and cardiovascular risks in individuals with type 2 diabetes and chronic kidney disease, finding significant reductions in key health outcomes.
The study evaluated the effects of semaglutide on vascular regenerative cell content in individuals with type 2 diabetes, finding significant increases compared to usual care.
The study evaluated the effects of semaglutide on cardiovascular events in individuals with overweight or obesity and established cardiovascular disease without diabetes, finding a 20% reduction in major adverse cardiovascular events.
Latest Evidence
Build your workspace to keep track of the latest diabetes research.